News & Analysis

Australian healthtech CliniCloud launches integration with US telehealth provider Doctor On Demand

- May 13, 2016 3 MIN READ

Following months of trials and testing with doctors overseas, Australian healthtech startup CliniCloud has officially launched its integration with US telehealth provider Doctor On Demand. The integration between the two companies will bring the tools of the doctor’s office directly into people’s homes.

CliniCloud is an Australian-born, now US-based startup that allows individuals to monitor their health from home through an app-based medical kit. The kit consists of a digital stethoscope and non-contact thermometer, which is connected to the cloud through app-based technology.

The app guides users through either a quick or full checkup with intuitive prompts for people without medical training who want to perform checkups from the comfort of their own home. The recordings of basic vital sign checkups like temperature and heart and lung sounds can be sent off to a network of on-demand medical professionals for processing.

The partnership with Doctor On Demand is part of the startup’s strategy to crack the US market and transform the average American’s access to quality healthcare. In America, the inequality in healthcare boils down to three issues – disparities in health, disparities in care, and finally inequality in health insurance.

For the last decade technology has increasingly changed the way healthcare is offered to American citizens with healthtech startups looking to address these issues of health inequality.

Doctor On Demand has seen enormous success and growth in the US, raising a total of US$86.75 million in a series of three funding rounds. The telehealth provider allows for fast, easy, and cost-effective video consultations with board-certified physicians, psychiatrists, and licensed psychologists via a smartphone or computer.

With access to CliniCloud’s stethoscope and non-contact thermometer, doctors can use even more physical examination findings to inform their decision making. Patients will be able to record and then forward to their doctors their vital signs and physicians can now combine that information with CliniCloud temperature recording to better identify patients who are more likely to have serious conditions.

Cofounder and CEO of CliniCloud, Andrew Lin, said, “The opportunities for smart technology to change how Americans access quality healthcare and improve the way we live are endless, and Doctor On Demand is at the forefront of innovation in this space. Together we’re enabling people to get a more comprehensive medical examination from the comfort of home.”

Doctor On Demand has access to tens of millions of Americans through its employer or health plan at no cost or subsidised fee. The service is available for a flat fee of US$40 per physician visit. Customers who purchase a CliniCloud device will receive their first visit with Doctor On Demand for free.

The news comes a few months after CliniCloud raised $5 million in a funding round led by Tencent and Ping An Ventures. The kit has now been launched globally after securing a retail partnership with US giant Best Buy. Following a successful trial of Doctor on Demand’s user base, CliniCloud’s app is also now available on iOS and Android and is priced at US$149.

Australia has been part of a greater worldwide initiative to disrupt and transform the health industry and relieve the burden on overcrowded hospitals and overburdened GPs. Corporate accelerator Slingshot this year partnered with HCF to launch a healthtech-focused accelerator program, HCF Catalyst. The program saw nine startups develop and pitch their ideas to the public this week, showcasing their tech-driven health products.

The participants have already found some success, with CancerAid, an app aiming to improve cancer care worldwide by empowering patients through the provision of personalised information, recently signing term sheets worth over $100,000 with a number of new customers, and raising more than $400,000 towards its larger $1 million round.

Image: Dr Andrew Lin and Dr Hon Weng Chong. Source: Supplied.